Straits Times Index
3,293.41 +0.72 (+0.02%) Nikkei
38,271.22 -2.83 (-0.01%) Hang Seng
18,200.60 +437.57 (+2.46%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,438.74 -2,485.64 (-4.15%) CMC Crypto 200
1,258.93 -11.81 (-0.93%)
NVO Jan 2025 87.500 call
| Previous close | 44.91 |
| Open | 45.15 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 87.50 |
| Expiry date | 2025-01-17 |
| Day's range | 44.91 - 45.15 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Apple, Novo Nordisk earnings, jobless claims: What to watch
A number of companies release their quarterly earning reports on Thursday, including Apple (AAPL), Novo Nordisk (NVO), Shell (SHEL), ConocoPhillips (COP), Cigna (CI), Coinbase (COIN), Moderna (MRNA), DraftKings (DKNG), Kellanova (K), United States Steel (X), and more. On the economic front, jobless claims for the week ending on April 27 will be released. Economists expect claims to rise to 212,000 from 207,000 the prior week. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Nicholas Jacobino
ReutersObesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast
LONDON (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday as it posted first-quarter operating profit above analyst forecasts. Novo said it now expects sales growth this year of between 19% and 27% in local currencies, compared to the previously guided range for 18% to 26% growth.
GlobeNewswireNovo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales in North America Operations increased by 34% in Danish kroner (35% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in Danish kroner (11% at CER).Sales within Diabetes
